Calidi Biotherapeutics Statistics Share Statistics Calidi Biotherapeutics has 2.88M
shares outstanding. The number of shares has increased by 0.02%
in one year.
Shares Outstanding 2.88M Shares Change (YoY) 0.02% Shares Change (QoQ) 0.06% Owned by Institutions (%) 20.15% Shares Floating 2.69M Failed to Deliver (FTD) Shares 779,692 FTD / Avg. Volume 48.86%
Short Selling Information The latest short interest is 270.02K, so 7.55% of the outstanding
shares have been sold short.
Short Interest 270.02K Short % of Shares Out 7.55% Short % of Float 8.05% Short Ratio (days to cover) 1.47
Valuation Ratios The PE ratio is -0.41 and the forward
PE ratio is -0.28.
Calidi Biotherapeutics's PEG ratio is
0.01.
PE Ratio -0.41 Forward PE -0.28 PS Ratio 0 Forward PS n/a PB Ratio 5.98 P/FCF Ratio -0.47 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Calidi Biotherapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.08,
with a Debt / Equity ratio of 4.59.
Current Ratio 1.08 Quick Ratio 1.08 Debt / Equity 4.59 Debt / EBITDA -0.32 Debt / FCF -0.36 Interest Coverage -23.34
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-790.82K Employee Count 28 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 14K Effective Tax Rate -0.06%
Stock Price Statistics The stock price has increased by -88.58% in the
last 52 weeks. The beta is 1.08, so Calidi Biotherapeutics's
price volatility has been higher than the market average.
Beta 1.08 52-Week Price Change -88.58% 50-Day Moving Average 5.06 200-Day Moving Average 9.59 Relative Strength Index (RSI) 30.1 Average Volume (20 Days) 1,595,810
Income Statement
Revenue n/a Gross Profit -1.53M Operating Income -21.78M Net Income -22.14M EBITDA -21.78M EBIT -22.57M Earnings Per Share (EPS) -35.7
Full Income Statement Balance Sheet The company has 9.59M in cash and 7.04M in
debt, giving a net cash position of 2.56M.
Cash & Cash Equivalents 9.59M Total Debt 7.04M Net Cash 2.56M Retained Earnings -121.72M Total Assets 9.35M Working Capital 696K
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -19.69M
and capital expenditures -16K, giving a free cash flow of -19.71M.
Operating Cash Flow -19.69M Capital Expenditures -16K Free Cash Flow -19.71M FCF Per Share -29.67
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CLDI does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for CLDI.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 5, 2025. It was a
backward
split with a ratio of 1:12.
Last Split Date Aug 5, 2025 Split Type backward Split Ratio 1:12
Scores Altman Z-Score -26.19 Piotroski F-Score 3
